The industry, patients, and clinicians should now seek a better understanding of the criteria and conditions, including any potential relationship with the health technology assessment review recommendations and any obligation on the company if DFMO does not successfully navigate the reimbursement process. …
Worth knowing the criteria used to justify the creation of the DFMO 'bridging' fund
July 16, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The Government can demonstrate that its support for women's health is more than talk
August 26, 2024 - - Latest News -
'This is in stark contrast to other parts of the world where new RSV immunisations have been readily embraced'
August 26, 2024 - - Latest News -
July outcomes disappoint but committee appears to relent on risk share arrangement
August 26, 2024 - - Latest News -
AbbVie Australia makes the list of best places to work for 11th year
August 23, 2024 - - Latest News -
A post-COVID 'transition period for the company as it returns to 'business as usual'
August 23, 2024 - - Latest News -
Government moves quickly to clarify pricing legislation following Federal Court victory
August 23, 2024 - - Latest News -
The 'Week in Review' Podcast - 22 August
August 22, 2024 - - Podcast